Evidence map›Paper›PMID 42503070›Full record

ArticleAngiogenesis2026

Endothelial VEGFR2 insufficiency promotes the transition of lymphatic to hematopoietic transcriptional programs.

Taotao Li, Xudong Cao, Fei Zhou, Xiujuan Li, Wenjuan Ma, Xiuyan Zhang, Haoyu Zhong, Beibei Xu, Man Chu, Xiwen Jia and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Angiogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Taotao Li *Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Xudong Cao *Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Fei Zhou *Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Xiujuan LiCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Wenjuan MaCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Xiuyan ZhangCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Haoyu ZhongCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Beibei XuCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Man ChuCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Xiwen JiaCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Kai DingCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Xin ShenCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Yahui LiuCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Yun ZhaoCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China.
Zhen ZhangPediatric Translational Medicine Institute and Pediatric Congenital Heart Disease Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Junhao HuInterdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
Young-Kwon HongDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Lena Claesson-WelshRudbeck, Beijer and SciLifeLab Laboratories, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Yulong HeCyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Cam-Su Genomic Resource Center, Suzhou Medical College of Soochow University, Suzhou, China. heyulong@suda.edu.cn.ORCID https://orcid.org/0000-0002-0099-3749

Funding

China Postdoctoral Science Foundation 2024M762300National Key Research and Development Program of China 2021YFA0805000National Natural Science Foundation of China 81773081National Natural Science Foundation of China 82470518Natural Science Foundation of Jiangsu Province BK20240786Project of State Key Laboratory of Radiation Medicine and Protection GZN120 20 02Swedish Foundation for International Cooperation in Research and Higher Education CH2018-7817
6 · The paper itself

Abstract

Vascular endothelial growth factor receptor-2 (VEGFR2) is a key target for regulating the endothelial cell lineage and angiogenesis. It is also expressed by lymphatic endothelial cells (LECs) while its participation in lymphangiogenesis remains inadequately characterized. We demonstrate in this study that VEGFR2 is highly expressed in dermal initial lymphatic vessels and valves. The induced deletion of pan-endothelial Vegfr2 at the neonatal stage produced a potent suppression of dermal lymphatic growth, characterized by a thinner lymphatic diameter, a decreased number of LECs and lymphatic valves. Mechanistically, VEGFR2 insufficiency led to a dramatic decrease in lymphatic VEGFR3, a key regulator mediating signals for lymphatic growth and remodeling. RNA sequencing analysis revealed that GO terms enriched for downregulated genes included biological processes related to EC development while pathways related to hematopoiesis and immune responses were upregulated in the skin of Vegfr2 mutants compared with littermate controls. This was further confirmed by RNA-seq analysis of dermal tissues 48 h after endothelial Vegfr2 deletion. Consistently, targeting Vegfr2 in PROX1

Indexed as

Endothelial CellsHematopoiesisLymphangiogenesisLymphatic VesselsTranscription, GeneticVascular Endothelial Growth Factor Receptor-2AnimalsMiceProspero-Related Homeobox 1 ProteinVascular Endothelial Growth Factor Receptor-3Kdr protein, mouseProspero-Related Homeobox 1 ProteinVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-3Endothelial cell lineageLymphangiogenesisLymphatic endothelial cellTranscriptional programsVEGFR2VEGFR3

Identifiers

PMID42503070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.